201 related articles for article (PubMed ID: 29254080)
1. Rationale and Design of the Mechanistic Potential of Antihypertensives in Preclinical Alzheimer's (HEART) Trial.
Wharton W; Goldstein FC; Tansey MG; Brown AL; Tharwani SD; Verble DD; Cintron A; Kehoe PG
J Alzheimers Dis; 2018; 61(2):815-824. PubMed ID: 29254080
[TBL] [Abstract][Full Text] [Related]
2. The Rationale and Design of the Reducing Pathology in Alzheimer's Disease through Angiotensin TaRgeting (RADAR) Trial.
Kehoe PG; Blair PS; Howden B; Thomas DL; Malone IB; Horwood J; Clement C; Selman LE; Baber H; Lane A; Coulthard E; Passmore AP; Fox NC; Wilkinson IB; Ben-Shlomo Y
J Alzheimers Dis; 2018; 61(2):803-814. PubMed ID: 29226862
[TBL] [Abstract][Full Text] [Related]
3. Modulation of Renin-Angiotensin System May Slow Conversion from Mild Cognitive Impairment to Alzheimer's Disease.
Wharton W; Goldstein FC; Zhao L; Steenland K; Levey AI; Hajjar I
J Am Geriatr Soc; 2015 Sep; 63(9):1749-56. PubMed ID: 26389987
[TBL] [Abstract][Full Text] [Related]
4. The effects of ramipril in individuals at risk for Alzheimer's disease: results of a pilot clinical trial.
Wharton W; Stein JH; Korcarz C; Sachs J; Olson SR; Zetterberg H; Dowling M; Ye S; Gleason CE; Underbakke G; Jacobson LE; Johnson SC; Sager MA; Asthana S; Carlsson CM
J Alzheimers Dis; 2012; 32(1):147-56. PubMed ID: 22776970
[TBL] [Abstract][Full Text] [Related]
5. Neurofibrillary Tangles and Conversion to Mild Cognitive Impairment with Certain Antihypertensives.
Wharton W; Zhao L; Steenland K; Goldstein FC; Schneider JA; Barnes LL; Gearing M; Yasar S
J Alzheimers Dis; 2019; 70(1):153-161. PubMed ID: 31177216
[TBL] [Abstract][Full Text] [Related]
6. Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer's disease.
Modeste ES; Ping L; Watson CM; Duong DM; Dammer EB; Johnson ECB; Roberts BR; Lah JJ; Levey AI; Seyfried NT
Mol Neurodegener; 2023 Jul; 18(1):48. PubMed ID: 37468915
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal Fluid Changes in the Renin-Angiotensin System in Alzheimer's Disease.
Kehoe PG; Al Mulhim N; Zetterberg H; Blennow K; Miners JS
J Alzheimers Dis; 2019; 72(2):525-535. PubMed ID: 31594235
[TBL] [Abstract][Full Text] [Related]
8. Anti-Hypertensive Drugs Moderate the Relationship of Blood Pressure with Alzheimer's Pathologies and Neurodegenerative Markers in Non-Demented Hypertensive Older Adults.
Guo Y; Tan CC; Tan MS; Tan L; Xu W
J Prev Alzheimers Dis; 2024; 11(3):672-683. PubMed ID: 38706283
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study.
Timmers M; Streffer JR; Russu A; Tominaga Y; Shimizu H; Shiraishi A; Tatikola K; Smekens P; Börjesson-Hanson A; Andreasen N; Matias-Guiu J; Baquero M; Boada M; Tesseur I; Tritsmans L; Van Nueten L; Engelborghs S
Alzheimers Res Ther; 2018 Aug; 10(1):85. PubMed ID: 30134967
[TBL] [Abstract][Full Text] [Related]
10. Renin-Angiotensin System and Alzheimer's Disease Pathophysiology: From the Potential Interactions to Therapeutic Perspectives.
Ribeiro VT; de Souza LC; Simões E Silva AC
Protein Pept Lett; 2020; 27(6):484-511. PubMed ID: 31886744
[TBL] [Abstract][Full Text] [Related]
11. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
[TBL] [Abstract][Full Text] [Related]
12. Race modifies the relationship between cognition and Alzheimer's disease cerebrospinal fluid biomarkers.
Howell JC; Watts KD; Parker MW; Wu J; Kollhoff A; Wingo TS; Dorbin CD; Qiu D; Hu WT
Alzheimers Res Ther; 2017 Nov; 9(1):88. PubMed ID: 29096697
[TBL] [Abstract][Full Text] [Related]
13. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
[TBL] [Abstract][Full Text] [Related]
14. Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification.
Izzo NJ; Yuede CM; LaBarbera KM; Limegrover CS; Rehak C; Yurko R; Waybright L; Look G; Rishton G; Safferstein H; Hamby ME; Williams C; Sadlek K; Edwards HM; Davis CS; Grundman M; Schneider LS; DeKosky ST; Chelsky D; Pike I; Henstridge C; Blennow K; Zetterberg H; LeVine H; Spires-Jones TL; Cirrito JR; Catalano SM
Alzheimers Dement; 2021 Aug; 17(8):1365-1382. PubMed ID: 33559354
[TBL] [Abstract][Full Text] [Related]
15. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
16. The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition.
Hajjar I; Hart M; Milberg W; Novak V; Lipsitz L
BMC Geriatr; 2009 Nov; 9():48. PubMed ID: 19922631
[TBL] [Abstract][Full Text] [Related]
17. A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer's disease.
van Dyck CH; Mecca AP; O'Dell RS; Bartlett HH; Diepenbrock NG; Huang Y; Hamby ME; Grundman M; Catalano SM; Caggiano AO; Carson RE
Alzheimers Res Ther; 2024 Jan; 16(1):20. PubMed ID: 38273408
[TBL] [Abstract][Full Text] [Related]
18. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
[TBL] [Abstract][Full Text] [Related]
19. Telmisartan/17β-estradiol mitigated cognitive deficit in an ovariectomized rat model of Alzheimer's disease: Modulation of ACE1/ACE2 and AT1/AT2 ratio.
Abdelkader NF; Abd El-Latif AM; Khattab MM
Life Sci; 2020 Mar; 245():117388. PubMed ID: 32007576
[TBL] [Abstract][Full Text] [Related]
20. Population-based discovery and Mendelian randomization analysis identify telmisartan as a candidate medicine for Alzheimer's disease in African Americans.
Zhang P; Hou Y; Tu W; Campbell N; Pieper AA; Leverenz JB; Gao S; Cummings J; Cheng F
Alzheimers Dement; 2023 May; 19(5):1876-1887. PubMed ID: 36331056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
